ACADIA Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. 

CEO
Catherine Owen Adams
CEOCatherine Owen Adams
Employees
798
Employees798
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1993
Founded1993
Employees
798
Employees798

ACAD Key Statistics

Market cap
3.65B
Market cap3.65B
Price-Earnings ratio
8.96
Price-Earnings ratio8.96
Dividend yield
Dividend yield
Average volume
1.75M
Average volume1.75M
High today
$21.54
High today$21.54
Low today
$20.94
Low today$20.94
Open price
$21.07
Open price$21.07
Volume
3.05M
Volume3.05M
52 Week high
$28.35
52 Week high$28.35
52 Week low
$13.40
52 Week low$13.40

Stock Snapshot

As of today, ACADIA Pharmaceuticals(ACAD) shares are valued at $21.35. The company's market cap stands at 3.65B, with a P/E ratio of 8.96.

During the trading session on 2026-03-17, ACADIA Pharmaceuticals(ACAD) shares reached a daily high of $21.54 and a low of $20.94. At a current price of $21.35, the stock is +2.0% higher than the low and still -0.9% under the high.

Trading activity shows a volume of 3.05M, compared to an average daily volume of 1.75M.

Over the past 52 weeks, ACADIA Pharmaceuticals(ACAD) stock has traded between a high of $28.35 and a low of $13.40.

Over the past 52 weeks, ACADIA Pharmaceuticals(ACAD) stock has traded between a high of $28.35 and a low of $13.40.

ACAD News

Simply Wall St 8h
ACADIA Pharmaceuticals Is Down 5.3% After EMA Rejects Trofinetide In Rett Review - What's Changed

Earlier in March 2026, ACADIA Pharmaceuticals received a formal negative opinion from the EMA’s CHMP on its marketing application for trofinetide in Rett syndro...

ACADIA Pharmaceuticals Is Down 5.3% After EMA Rejects Trofinetide In Rett Review - What's Changed

Analyst ratings

71%

of 21 ratings
Buy
71.4%
Hold
23.8%
Sell
4.8%

People also own

Based on the portfolios of people who own ACAD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.